Dariusz Pytel to Antineoplastic Agents
This is a "connection" page, showing publications Dariusz Pytel has written about Antineoplastic Agents.
Connection Strength
0.411
-
Use of Small-molecule Inhibitory Compound of PERK-dependent Signaling Pathway as a Promising Target-based Therapy for Colorectal Cancer. Curr Cancer Drug Targets. 2020; 20(3):223-238.
Score: 0.105
-
Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment. Curr Med Chem. 2019; 26(8):1425-1445.
Score: 0.098
-
Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem. 2009 Jan; 9(1):66-76.
Score: 0.049
-
[The role of oncogenic tyrosine kinases in the cellular response to anticancer therapy]. Postepy Hig Med Dosw (Online). 2007 Dec 14; 61:819-27.
Score: 0.046
-
Imatinib (STI571) inhibits DNA repair in human leukemia oncogenic tyrosine kinase-expressing cells. Z Naturforsch C J Biosci. 2006 Nov-Dec; 61(11-12):896-902.
Score: 0.042
-
[Tyrosine kinases. New target of anticancer therapy]. Postepy Biochem. 2005; 51(3):251-60.
Score: 0.037
-
Inhibition of PERK-dependent pro-adaptive signaling pathway as a promising approach for cancer treatment. Pol Przegl Chir. 2017 Jun 30; 89(3):7-10.
Score: 0.022
-
DNA damage and repair of head and neck cancer cells after radio- and chemotherapy. Z Naturforsch C J Biosci. 2009 Jul-Aug; 64(7-8):601-10.
Score: 0.013